Product Description
Carfilzomib injection is used alone and in combination with dexamethasone, daratumumab and dexamethasone, or lenalidomide (Revlimid) and dexamethasone to treat people with multiple myeloma (a type of cancer of the bone marrow) who have already been treated with other medications. Carfilzomib is in a class of medications called proteasome inhibitors. It works by stopping or slowing the growth of cancer cells in your body. (Sourced from: https://medlineplus.gov/druginfo/meds/a612031.html)
Mechanisms of Action: Proteasome Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay
Approved Indications: Multiple Myeloma
Known Adverse Events: Anemia | Thrombocytopenia | Dyspnea | Diarrhea
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: BeiGene
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Korea, Lithuania, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Saudi Arabia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States
Active Clinical Trial Count: 66
Highest Development Phases
Phase 3: Multiple Myeloma|Stem Cell Transplant
Phase 2: Kidney Diseases|Kidney Transplant|Leukemia, Plasma Cell|Lymphoma|Waldenstrom Macroglobulinemia
Phase 1: Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IsKia TRIAL | P3 |
Active, not recruiting |
Multiple Myeloma |
2030-05-20 |
|
| jRCT2071230095 | P3 |
Not yet recruiting |
Multiple Myeloma |
2030-02-28 |
|
| Isa-CAPED MM | P2 |
Recruiting |
Multiple Myeloma |
2029-12-31 |
|
| CA057-008 | P3 |
Unknown Status |
Multiple Myeloma |
2029-07-30 |